Medpace Holdings, Inc. MEDP Reimbursed out-of-pocket expenses — Total direct costs

Other product segments

Similar metrics at other companies

MGMReimbursed costs — Cost of revenues

$11.88M+2.8%

CBREProject Management — Pass-through costs

$927M+12.1%

AJGReimbursements

$42M+7.7%

HReimbursed costs — Costs of goods and services sold

$963M+6.8%

AJGRisk Management — Cost Reimbursements

$42M+7.7%

WTWReimbursed Expenses — Portion Of Revenue

0.3%0.0pp

Questions, answered.

What is Medpace Holdings, Inc.'s reimbursed out-of-pocket expenses — total direct costs?

Medpace Holdings, Inc. (MEDP) reported reimbursed out-of-pocket expenses — total direct costs of $312M in Q1 2026.

How has Medpace Holdings, Inc.'s reimbursed out-of-pocket expenses — total direct costs changed year-over-year?

Medpace Holdings, Inc.'s reimbursed out-of-pocket expenses — total direct costs increased by 54.1% year-over-year, from $202.4M to $312M.

What is the long-term trend for Medpace Holdings, Inc.'s reimbursed out-of-pocket expenses — total direct costs?

Over 4 years (2021 to 2025), Medpace Holdings, Inc.'s reimbursed out-of-pocket expenses — total direct costs has grown at a 29.1% compound annual growth rate (CAGR), from $373.13M to $1.04B.

What does reimbursed out-of-pocket expenses — total direct costs mean?

The total amount of project-related expenses paid by the company that are subsequently billed back to clients for reimbursement.

How do you interpret reimbursed out-of-pocket expenses — total direct costs?

An increase in these costs generally reflects higher clinical trial activity and project volume, while a decrease may indicate lower trial intensity or improved cost-containment measures on pass-through items.

How does reimbursed out-of-pocket expenses — total direct costs compare across companies?

Most contract research organizations report similar pass-through cost categories, though the accounting treatment of these expenses as revenue versus cost can vary significantly across the industry.